FDA Issues Draft Guidance on Software as a Medical Device for Mental Health Apps

The U.S. Food and Drug Administration updated its regulatory framework for software as a medical device that targets stress management. The changes spell out definitions, risk categories, and evidence standards that developers must meet. These steps seek to encourage innovation in digital tools while preserving safety and performance expectations.

What this means

The framework offers developers clearer routes for lower-risk products and stricter scrutiny for higher-risk ones. Real-world evidence can now play a larger role in submissions, which may shorten review times for certain applications. Patients and clinicians gain more predictable information on which tools fall under FDA oversight.

FDA's tiered risk-based framework for regulating software as a medical device targeting stress management, highlighting classification criteria and evidence requirements.

Key takeaways

• The FDA clarified definitions, risk classification, and evidentiary standards for SaMD solutions intended for stress management [1].
• Digital therapeutics for stress management may use real-world evidence to support claims of effectiveness and performance [2].
• The agency intends to streamline pathways for lower-risk products while keeping robust oversight for high-risk items [3].
• Stakeholders note that continuous updates will be needed as digital health technologies change.

Key Features of the Updated Framework

The FDA outlined a risk-based approach that ties regulatory requirements to the intended use and potential impact of each product. Lower-risk stress management tools face lighter premarket demands. Higher-risk applications require more clinical data before they reach the market.

Classification Under SaMD Regulations

Software qualifies as a medical device when it provides therapeutic output for stress management without hardware. The agency assigns risk levels based on the severity of the condition addressed and the role the software plays in treatment decisions. This classification determines the depth of evidence needed.

Premarket Submission and Clinical Evidence Requirements

Developers must submit data that demonstrate safety and effectiveness before marketing. Real-world evidence from actual use settings can supplement traditional studies in these filings. The guidance stresses transparent reporting of performance metrics over time.

Limitations

The guidance applies mainly to the U.S. market and may receive further revisions as technologies advance. Not every stress management app meets the SaMD definition, so many tools remain outside FDA review.

Last updated: August 26, 2026